Literature DB >> 14646693

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.

Kimie Sai1, Nahoko Kaniwa, Masaya Itoda, Yoshiro Saito, Ryuichi Hasegawa, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Kuniaki Shirao, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Yutaka Kitamura, Naoyuki Kamatani, Shogo Ozawa, Jun-Ichi Sawada.   

Abstract

We performed comprehensive haplotyping of ABCB1/MDR1 gene blocks using 49 genetic polymorphisms, including seven novel ones, obtained from 145 Japanese subjects. The ABCB1/MDR1 gene was divided into four blocks (Blocks -1, 1, 2, and 3) based on linkage disequilibrium analysis of polymorphisms. Using an expectation-maximization based program, 1, 2, 8, and 3 haplotype groups (3, 12, 32, and 18 haplotypes) were identified in Blocks -1, 1, 2, and 3, respectively. Within Block 2, haplotype groups *1, *2, *4, *6, and *8 reported by Kim and colleagues (Clin Pharmacol Ther 2001; 70:189-199) were found, and additional three groups (*9 to *11) were newly defined. We analyzed the association of haplotypes with the renal clearance of irinotecan and its metabolites in 49 Japanese cancer patients given irinotecan intravenously. There was a significant association of the *2 haplotype in Block 2, which includes 1236C>T, 2677G>T and 3435C>T, with a reduced renal clearance of those compounds. Moreover, tendencies of reduced and increased renal clearance were also observed with *1f in Block 2 and *1b in Block 3, respectively. These findings suggest that the P-glycoprotein encoded by ABCB1/MDR1 in the proximal tubules plays a substantial role in renal exclusion of drugs and, moreover, that block-haplotyping is valuable for pharmacogenetic studies. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14646693     DOI: 10.1097/00008571-200312000-00005

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  43 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Personalized medicine: is it a pharmacogenetic mirage?

Authors:  Rashmi R Shah; Devron R Shah
Journal:  Br J Clin Pharmacol       Date:  2012-10       Impact factor: 4.335

3.  Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.

Authors:  Catherine Bourguinat; Joseph Kamgno; Michel Boussinesq; Charles D Mackenzie; Roger K Prichard; Timothy G Geary
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

4.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

5.  Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.

Authors:  T M Bosch; V D Doodeman; P H M Smits; I Meijerman; J H M Schellens; J H Beijnen
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

6.  ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Authors:  M Li; E L Seiser; R M Baldwin; J Ramirez; M J Ratain; F Innocenti; D L Kroetz
Journal:  Pharmacogenomics J       Date:  2016-11-15       Impact factor: 3.550

Review 7.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

Review 8.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Authors:  King Leung Fung; Michael M Gottesman
Journal:  Biochim Biophys Acta       Date:  2009-03-11

9.  A linkage and association analysis study in the multidrug resistance gene 1 (mdr1) in renal patients.

Authors:  Mohammad R Bazrafshani; Kay V Poulton; Merat Mahmoodi
Journal:  Int J Mol Epidemiol Genet       Date:  2012-11-15

10.  Clinical significance of ABCB1 genotyping in oncology.

Authors:  Alma Hamidovic; Kristine Hahn; Jill Kolesar
Journal:  J Oncol Pharm Pract       Date:  2009-04-28       Impact factor: 1.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.